ViroPharma Incorporated (VPHM)

ViroPharma Incorporated, a biotechnology company, develops and commercializes therapeutic products that address serious diseases in the United States and internationally. The company markets and sells Cinryze, a C1 esterase inhibitor therapy for the routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema, a life-threatening genetic disorder; and Vancocin HCl capsule, an oral capsule formulation for the treatment of C. difficile-associated diarrhea (CDAD) and to treat enterocolitis caused by Staphylococcus aureus, including methicillin-resistant strains. It also offers Plenadren, an orphan drug for treatment of adrenal insufficiency in adults; and Buccolam, an oromucosal solution for treatment of prolonged, acute, and convulsive seizures in infants, toddlers, children, and adolescents. The company’s development programs include Cinryze, a C1 esterase inhibitor for management of hereditary angioedema; maribavir for cytomegalovirus infection; and VP 20621, a non-toxigenic strain of C. difficile for the treatment and prevention of CDAD. Its clinical stage drug candidate comprises VP-20629 for the treatment of Friedreich’s Ataxia. The company sells its products directly to wholesale drug distributors and specialty pharmacies/distributors. It has a license agreement with GlaxoSmithKline to develop and commercialize maribavir, an antiviral compound. ViroPharma Incorporated was founded in 1994 and is headquartered in Exton, Pennsylvania. As of January 23, 2014, ViroPharma Inc. operates as a subsidiary of Shire Pharmaceutical Holdings Ireland Limited.